跳转至内容
Merck
CN

C2460000

氯氮平标准液

European Pharmacopoeia (EP) Reference Standard

别名:

8-氯-11-(4-甲基-1-哌嗪基)-5H-二苯并[b,e][1,4]二氮杂卓

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C18H19ClN4
化学文摘社编号:
分子量:
326.82
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氯氮平标准液, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

SMILES string

CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24

InChI key

QZUDBNBUXVUHMW-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

clozapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

正在寻找类似产品? 访问 产品对比指南

Application

Clozapine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Chun-Hsin Chen et al.
The Journal of clinical psychiatry, 74(5), e424-e430 (2013-06-14)
Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia. Whether or not the beneficial effects can be sustained after discontinuation of metformin needs to be evaluated. We conducted a 24-week randomized
Shalini Jain et al.
The Journal of clinical investigation, 123(4), 1750-1762 (2013-03-13)
Type 2 diabetes (T2D) has emerged as a major threat to human health in most parts of the world. Therapeutic strategies aimed at improving pancreatic β cell function are predicted to prove beneficial for the treatment of T2D. In the
Bianca A Silva et al.
Nature neuroscience, 16(12), 1731-1733 (2013-11-12)
The neural circuits mediating fear to naturalistic threats are poorly understood. We found that functionally independent populations of neurons in the ventromedial hypothalamus (VMH), a region that has been implicated in feeding, sex and aggression, are essential for predator and
Chao-Cheng Lin et al.
Journal of clinical psychopharmacology, 33(2), 211-214 (2013-02-21)
Clozapine is the most effective antipsychotic for patients with treatment-refractory schizophrenia, but many adverse effects are noted. Clinicians usually hesitate to switch from clozapine to other antipsychotics because of the risk of a re-emergence or worsening of the psychosis, although
Jimmi Nielsen et al.
The Journal of clinical psychiatry, 74(6), 603-613 (2013-07-12)
To identify the outcome of potentially serious adverse effects of clozapine, particularly those frequently cited as reasons for clozapine discontinuation, and to characterize management strategies for adverse effects that do not warrant discontinuation. A structured search was performed of PubMed

商品

HPLC-UV quantitative analysis of four clozapine-related substances in clozapine API as per Ph. Eur. Monograph using Purospher® Star RP-18 endcapped column.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持